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Abstract
Background: COX-2 inhibitors, such as celecoxib, and ubiquitin-proteasome pathway inhibitors,
such as bortezomib, can down-regulate NF-κB, a transcription factor implicated in tumor growth.
The objective of this study was to determine the maximum tolerated dose and dose-limiting
toxicities of bortezomib in combination with celecoxib in patients with advanced solid tumors.
Methods: Patients received escalating doses of bortezomib either on a weekly schedule (days 1,
8, 15, 22, and 29 repeated every 42 days) or on a twice-weekly administration schedule (days 1, 4,
8, and 11 repeated every 21 days), in combination with escalating doses of celecoxib twice daily
throughout the study period from 200 mg to 400 mg twice daily.
Results: No dose-limiting toxicity was observed during the study period. Two patients had stable
disease lasting for four and five months each, and sixteen patients developed progressive disease.
Conclusion: The combination of bortezomib and celecoxib was well tolerated, without dose
limiting toxicities observed throughout the dosing ranges tested, and will be studied further at the
highest dose levels investigated.
Trial registration number: NCT00290680.
Background
The ubiquitin-proteasome pathway plays an important
role in cell cycle regulation, neoplastic growth, and metas-
tasis [1,2]. At the heart of this degradative pathway is the
26S proteasome, an adenosine triphosphate-dependent
protease. The 26S proteasome consists of a core 20S parti-
cle, which contains the catalytic proteinase functions,
symmetrically bound to two copies of the regulatory 19S
particle. Proteolytic removal of damaged or misfolded
ubiquitinated proteins is an important part of the home-
ostatic function of the 26S proteasome. Additionally, the
26S proteasome is vital in degrading regulatory proteins
that govern cell cycle, transcription factor activation, cell
trafficking, and apoptosis.
The ubiquitin-proteasome pathway is responsible for the
ordered degradation of several regulatory proteins neces-
sary for cells to progress through the cell cycle. The tumor
suppressor p53, which acts as a negative regulator of cell
growth, is one example of targeted ubiquitin-proteasome
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mediated degradation. p53 is required for the transcrip-
tion of a number of genes involved in cell cycle control
and DNA synthesis. p53 also plays an important role in
apoptosis induced by cellular damage [3]. Cyclins and the
cyclin-dependent kinase inhibitors p21 and p27 are also
regulated by proteasome-dependent proteolysis [4]. Both
p21 and p27 can induce cell cycle arrest by inhibiting the
cyclin D-, E-, and A-dependent kinases [5].
The ubiquitin-proteasome pathway also plays an impor-
tant role in transcriptional regulation. Nuclear factor-κB
(NF-κB) is a key transcription factor, whose activation is
regulated by proteasome-mediated degradation of the
inhibitor protein I kappa B alpha-associated protein
kinase (IκBa) [4,5]. Cell adhesion molecules such as E-
selectin, ICAM-1, and VCAM-1, are regulated by NF-κB
and are involved in the development of angiogenesis and
tumor metastasis in vivo [4]. During metastasis, these
molecules direct the adhesion and extravasation of tumor
cells from the vasculature to distant tissue sites within the
body. Additionally, many cell types require NF-κB to
maintain cell viability as an anti-apoptotic controlling fac-
tor or growth factor [4]. Inhibiting NF-κB activation by
stabilizing the IκBa protein potentiates apoptosis of can-
cer cells to environmental stresses and cytotoxic agents.
Another enzyme recently targeted for cancer prevention
and treatment, cyclooxygenase (COX)-2, has garnered
increasing interest due to substantial epidemiologic,
experimental, pathologic, and clinical evidence suggesting
that nonsteroidal anti-inflammatory drugs (NSAIDs) pos-
sess anticancer properties [6-8]. NSAIDs are thought to
exert their anti-inflammatory effects by inhibiting pros-
taglandin synthesis through nonspecific inhibition of
COX enzymes. Prostaglandins, in particular prostaglan-
din E2, appear to be important in oncogenesis due to their
effects on cellular adhesion, immune surveillance, and
apoptosis [9]. Compared with normal tissues, cancers
have been shown to over-express prostaglandins [10-17].
In several animal and human models, inhibiting prostag-
landin synthesis by blocking COX-2 appears to protect
against oncogenesis in many tissue types including:
breast, colon, esophageal, lung, skin, and head and neck
cancers [6,7,10-16].
COX-2 is undetectable in most normal tissues; however, it
is induced at sites of inflammation by cytokines, growth
factors, tumor promoters, and is over-expressed in neopla-
sia [17]. Several mechanisms have been proposed to
explain the role of COX-2 in tumorigenesis, including
stimulating cancer cell proliferation, enhancing angiogen-
esis, and inhibiting apoptosis [18,19]. In vitro inhibition
of COX-2 with targeted molecules is thought to promote
apoptosis of cancer cells through inhibition of NF-kB acti-
vation [20].
Both COX-2 inhibitors and ubiquitin-proteasome path-
way inhibitors down-regulate NF-κB and their combina-
tion is an interesting opportunity to explore clinical
synergy with these two classes of agents. The ubiquitin-
proteasome pathway is involved in NF-κB regulation
through its impact on degradation of IκB and release of
NF-κB for translocation from the cytoplasm to the nucleus
[21]. Inhibition of IκB degradation by proteasome inhibi-
tion can limit the actions of NF-κB rendering tumor cells
more prone to apoptosis. The combination of the NSAID
sulindac and bortezomib was found to be synergistic both
in vitro, in colon cancer cell lines, and in vivo, in a
xenograft model [22]. Additionally, the COX-2 inhibitor
celecoxib has been reported to induce apoptosis inde-
pendent of its COX-2 effects using NF-κB as a probably
target [23]. Consequently, given the relevance of the COX-
2 oncogene to numerous solid tumors, clinical evaluation
of a COX-2 inhibitor/proteasome inhibitor combination
is warranted in patients with solid tumors.
We therefore hypothesized that the combination of the
COX-2 inhibitor celecoxib and the ubiquitin-proteasome
pathway inhibitor bortezomib is a potentially active clin-
ical combination in the treatment of advanced solid
tumors. Therefore, we conducted a phase I study to deter-
mine the maximum tolerated dose (MTD) and toxicity
profile of bortezomib in combination with celecoxib.
Methods
Patient Selection
Patients with a stage IV histologically proven malignant
neoplasm (solid tumor) arising from any primary site
with the exception of bone marrow or lymphoid tissue
were eligible for this study. Other eligibility criteria
included: recurrent or progressive disease after chemo-
therapy or radiation or chemotherapy or radiotherapy-
naive disease that, due to the patient co-morbidities or
wishes, is not a candidate for standard treatment, no prior
therapy with bortezomib, Eastern Cooperative Oncology
Group (ECOG) performance status of 2 or less, neutrophil
count > 1500/mm3, platelets > 100,000/mm3, creatinine
< 2.0 mg/dl (or creatinine clearance of > 30 ml/minute),
bilirubin < 2 mg/dl, and age > 18 years. Previous radio-
therapy was permitted provided that it was completed
more than two weeks before enrollment. All subjects pro-
vided written informed consent.
The exclusion criteria were as follows: ≥ grade 2 peripheral
neuropathy, hypersensitivity to bortezomib, boron, or
mannitol, hypersensitivity to any of the COX-2 inhibitors,
hypersensitivity to sulfa drugs, hypersensitivity to other
NSAIDs, active gastrointestinal ulcer, or history of GI
bleeding resulting from prior therapy with NSAIDs, preg-
nancy, or actively breast-feeding. This study was approvedBMC Cancer 2007, 7:221 http://www.biomedcentral.com/1471-2407/7/221
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by the institutional review board of the Medical Univer-
sity of South Carolina.
Study Design
This was an open-label, single center, nonrandomized,
dose-escalating phase I study utilizing a modified Fibon-
acci design. Escalating doses of bortezomib were adminis-
tered as a short IV bolus on days 1, 4, 8, and 11 every 3
weeks or on days 1, 8, 15, 22 and 29 every 6 weeks along
with celecoxib orally twice a day. Each cycle was 21 days
or 42 days in length depending on the bortezomib admin-
istration assignment. The trial did not escalate above 1.3
mg/m2 of bortezomib twice weekly or 1.6 mg/m2 of bort-
ezomib weekly because previously reported single-agent
bortezomib trials have reported significant toxicities
above these doses [24,25]. Similarly, celecoxib was not
escalated above 400 mg twice daily due to emerging car-
diac toxicity data from other trials [26]. Three patients
were initially enrolled at each dosing level. If one patient
experienced a dose-limiting toxicity, an additional three
patients would be accrued to that level. However, if two
patients experience a dose-limiting toxicity no further
patients would be accrued to that dose level. No maximal
number of cycles was pre-specified and patients with sta-
ble or responding disease were encouraged to remain on
therapy in the absence of significant toxicites. For patients
who experienced a dose limiting toxicity (DLT), a dose
adjustment was allowed if it was felt that the patient was
benefiting from the therapy (responding or stable dis-
ease). The dose of each drug in this study is detailed in
Table 1.
Definition of dose-limiting toxicities and maximum 
tolerated dose
Only dose-limiting toxicities (DLTs) occurring during the
first cycle of therapy were used to define the maximum
tolerated dose (MTD). DLTs were defined as follows: any
documented grade IV granulocytopenia or thrombocyto-
penia possibly or probably due to protocol therapy, any
documented ≥ grade III non-hematologic toxicity (except
for grade III nausea or vomiting or diarrhea in the first
cycle but controlled to a maximum of grade II with anti-
emetic or anti-diarrheal therapy in a second cycle), inabil-
ity to deliver any chemotherapy on day 8 of cycle 1
because of neutrophil count < 1000/μl or platelet count <
50,000/μl, or the inability to begin a subsequent cycle of
chemotherapy within 14 days of the scheduled date due
to persisting hematologic or non-hematologic toxicity of
greater than grade 1.
Treatment Assessments
Response and progression were evaluated in this study
using the international guidelines proposed by the
Response Evaluation Criteria in Solid Tumors (RECIST)
Committee [27]. Baseline evaluations included physical
exam, serum chemistries, hepatic function testing, com-
plete blood counts, and computed tomography or mag-
netic resonance imaging at the discretion of the treating
physician. The same imagining modality and laboratory
evaluations were completed every two cycles to evaluate
for response or progression. Patients underwent a physical
exam, serum chemistries, and complete blood count eval-
uation on the first day of each cycle. Additionally, a com-
plete blood count was required on day 4 of the 21 day
cycles or day 8 of the 42 days cycles. Further, complete
blood count and serum chemistries were required on day
8 of the 21 day cycles or day 15 of the 42 day cycles. NCI
Common Toxicity Criteria Adverse Event version 3.0 crite-
ria were used to grade toxicities.
Results
Patient characteristics
Eighteen patients were enrolled from April 2005 to July
2006. All patients met the entry criteria and were treated
in accordance with protocol guidelines. The median age
of patients was 62 years and both males and females were
well represented. All patients had performance status of 2
or better and patients with a variety of tumor histologies
were enrolled (Table 2).
Toxicity and treatment cycles
No dose limiting toxicities were observed during the first
cycle of treatment for any patient and the maximal
planned dosages were achieved. Creatinine elevation,
neuropathy, and fatigue/weakness were the most com-
monly observed toxicities and a full toxicity report is
included (Table 3). From these results, we did not discern
specific synergistic toxicities from this combination and
dose level six has been selected for the subsequent phase
II study. The median number of cycles was two for cohort
Table 1: Bortezomib and celecoxib cohort dosing schedules
Cohorts Bortezomib (mg/m2) Bortezomib days of administration Celecoxib (mg PO bid)
Level 1 1.0 1, 8, 15, 22, 29 q42 days 200
Level 2 1.0 1, 4, 8, 11 q21 days 200
Level 3 1.3 1, 8, 15, 22, 29 q42 days 300
Level 4 1.3 1, 4, 8, 11 q21 days 300
Level 5 1.6 1, 8, 15, 22, 29 q42 days 400
Level 6 1.3 1, 4, 8, 11 q21 days 400BMC Cancer 2007, 7:221 http://www.biomedcentral.com/1471-2407/7/221
Page 4 of 6
(page number not for citation purposes)
one, two for cohort two, one for cohort three, two for
cohort four, one for cohort five, and two for cohort six.
One patient experienced stable disease for six cycles until
experiencing diarrhea, thought to be bacterial-induced,
and withdrew from the study. All other patients ended
treatment due to disease progression and no other
patients withdrew or were removed due to toxicities.
Tumor response
In this study all patients were evaluable for response by
RECIST criteria. Of the eighteen patients studied, sixteen
patients experienced progressive disease during the first
two cycles. One patient with adrenocortical cancer
(cohort 4) and another with renal cell cancer (cohort 2)
experienced 4.3 and 5.1 months of stable disease while on
protocol therapy.
Discussion
Both COX-2 inhibitors and ubiquitin-proteasome path-
way inhibitors down-regulate NF-κB. Combining these
two classes of agents is an interesting opportunity to
investigate potential clinical synergy with a combination
of drugs not known to have overlapping toxicities.
This is the first phase I study to combine bortezomib and
celecoxib in patients with advanced solid tumors. The pri-
mary endpoint of this study was to determine the maxi-
mal tolerated doses of these agents when taken in
combination. No dose-limiting toxicities were observed
during the first cycle of treatment at any dose-level and
cumulative toxicities were manageable.
In our phase I study, two patients with previously progres-
sive disease experienced stable disease on therapy. A
patient with metastatic adrenocortical cancer, previously
intolerant of mitotane, achieved stable disease for 4.3
months until progression. A second patient with papillary
renal cell carcinoma achieved stable disease for 5.1
months. This patient had documented tumor progression
on multi-agent chemotherapy prior to enrolling on this
trial.
Interesting new data have been reported for celecoxib and
bortezomib since our study began. Celecoxib has been
shown to potentially have single-agent activity in men
with PSA recurrence after local prostate cancer therapy
[28]. Also, patients with non-small cell lung cancer receiv-
ing single-agent bortezomib recently reported an 8%
response rate [29]. Similarly, a phase II trial of patients
with metastatic renal cell carcinoma reported a response
rate of 11% and 38% of patients reported stable disease
with bortezomib [30]. Conversely, no tumor responses
were seen in recent studies of bortezomib in metastatic
melanoma, breast cancer, or colorectal cancer [31-33].
Conclusion
In conclusion, the combination of bortezomib and
celecoxib was well tolerated across the dose levels investi-
gated. No dose-limiting toxicities were witnessed and we
plan to proceed with dose level six (bortezomib 1.3 mg/
m2 days 1, 4, 8, and 11 repeated every 21 days in combi-
nation with celecoxib 400 mg orally twice daily) in a sub-
sequent phase II study.
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